FDA OKs Neurostimulation Device for Opioid Withdrawal
DyAnsys Inc. announced that its auricular neurostimulation device, Drug Relief, received clearance from the FDA.
DyAnsys Inc. announced that its auricular neurostimulation device, Drug Relief, received clearance from the FDA. The device is a non-narcotic option to aid in alleviating opioid withdrawal symptoms.
"This device offers hope to those who are suffering from opioid addiction," said DyAnsys Chief Executive Officer Srini Nageshwar, a graduate of the Institute of Technology Madras.
Drug Relief sends electrical pulses through fine needles inserted in the ear over the course of 120 hours. The device stimulates the percutaneous electrical nerve field to reduce symptoms including anxiety, agitation, depression, nausea, and opiate cravings, and increase comfort and mobility for the patient.
Click to continue reading on
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025